Fund+
Venture capitalLeuven · Series A–Series B · 11 people tracked
Investment thesis
Fund+ is an open-ended fund dedicated to long-term equity investment in innovative Life Sciences companies, with a particular focus on Belgium. It aims to create sustainable shareholder value, help build a leadership position within the Life Sciences sector, and generate meaningful, beneficial societal impact.
Source: firm website, verified Aug 3, 2026.
Team · 11 people
from the firm's website & public directories
What they invest in
from 13 of 20 portfolio companiesBiotech ×12Healthtech ×8Medical Devices ×5Digital Health ×2Deep Tech ×1Hardware ×1
HQs:France×1Netherlands×1United States×1
Investments · 20 tracked
founders shown can be your intro pathBiotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Andreas Muehler(Executive Officer)Daniel Vitt(Executive Officer, Director)inJASON TARDIO(Executive Officer)GLENN WHALEY(Executive Officer)INDERPAL SINGH(Executive Officer)Patrick Walsh(Executive Officer)
Co-investorsBayern Kapitalbmp VenturesPontifax Venture CapitalOmega Funds
Astrivax develops virus-targeted immunotherapies using its Launch-iT platform to eliminate cancer-causing viruses before they lead to disease, with an initial focus on HPV-driven cancers.
BiotechHealthtech
Co-investorsKorysPMVV-Bio Ventures
Co-investorsNewton Biocapital
Coave Therapeutics is a biotech company developing gene therapies based on AAV vector engineering and genetic construct design, targeting neurodegenerative and ocular diseases.
BiotechHealthtechParis, FR
Co-investorsKurma PartnersSeroba Life SciencesV-Bio VenturesBpifranceInvusNovo Holdings+1 more
Co-investorsCapricorn Venture PartnersPMVQuest for GrowthV-Bio VenturesBioGeneration Ventures
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.
Biotech
Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in
BoardMichel Detheux(Chairman)in
Co-investorsEQT Life SciencesJDRF T1D Fund
EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
BiotechDigital HealthMedical Devices
Co-investorsNewton Biocapital
Co-investorsPMV
ExeVir is a clinical-stage biotech developing single domain antibody (VHH) therapies to prevent and treat infectious diseases, with an initial focus on COVID-19 and dengue.
BiotechDeep TechHealthtech
Co-investorsV-Bio VenturesVIVES Partners
EyeD Pharma is a clinical-stage pharmaceutical company developing sustained-release micro-implants and complex therapeutics for ophthalmic diseases such as glaucoma, dry eye, and back-of-the-eye conditions.
BiotechHealthtechMedical Devices
Indigo is developing an implantable continuous multi-metabolite monitoring (CMM) sensor based on silicon photonics that measures metabolites such as glucose, ketone, and lactate in real time, with data shown via a smartphone app.
Digital HealthHardwareMedical Devices
Danaë Delbeke(CTO and Founder)
Co-investorsimec.xpand
Clinical-stage biotech developing therapies for orphan CNS diseases; lead program MIN-102 in trials for X-linked Adrenoleukodystrophy and Friedreich's Ataxia.
Co-investorsCriteria Bio Ventures
Minoryx is a biopharmaceutical company that discovers and develops drug treatments for severe orphan diseases of the central nervous system, such as cerebral adrenoleukodystrophy and Rett syndrome.
BiotechHealthtech
Co-investorsChiesi VenturesCriteria Bio VenturesInvivo Capital PartnersKurma PartnersRoche Venture FundYsios Capital+1 more
Novadip develops a new class of regenerative tissue products aimed at accelerating the healing of large bone defects, bone non-union, and spine fusion in a single treatment.
BiotechHealthtechMedical Devices
Co-investorsNew Science VenturesVIVES Partners
Ona Therapeutics is a biotechnology company developing first-in-class antibody drug conjugates (ADCs) and antibody therapies targeting the molecular biology of treatment-refractory advanced cancers.
BiotechHealthtech
Co-investorsKorysMérieux Equity PartnersYsios CapitalAlta Life SciencesAsabys PartnersBpifrance+2 more
TargED Biopharmaceuticals is a Netherlands-based biotechnology company developing first-in-class biological drugs that use small antibodies (VHH) to deliver enzymes to sites of thrombosis for targeted thrombolysis.
BiotechMedical Devices
Co-investorsAndera PartnersCurie CapitalHadean VenturesRotripBioGeneration VenturesInkef+1 more
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersBioMedPartnersFrazier Life SciencesNextech InvestOCCIDENT
Exits · 2
IPOs and acquisitions across the tracked portfolioImmunicNASDAQ: IMUXTubulis GmbHacq. by Gilead Sciences
Portfolio news
latest coverage across their companiesImmunic · themarketsdaily.com · Aug 19, 2026
Ona Therapeutics · fiercebiotech.com · Aug 12, 2026
Coave Therapeutics · biopharminternational.com · May 26, 2026
Frequently asked questions
- How many investments has Fund+ made?
- Fund+ has 20 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does Fund+ invest at?
- Fund+ invests at the Series A, Series B stages.
- What is Fund+'s typical check size?
- Fund+ typically writes checks of $5.5M – $16.5M.
- What sectors does Fund+ focus on?
- Fund+ focuses on Biotech, Healthtech, Impact & Social Good, Longevity, Medical Devices.
- Where is Fund+ located?
- Fund+ is headquartered in Leuven, BE.
- Who does Fund+ co-invest with?
- Fund+ most often shares deals with V-Bio Ventures, PMV, Criteria Bio Ventures, among 28 tracked co-investors.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
The Dementia Discovery Fund (DDF), managed by SV Health Investors, is a family of specialized venture capital funds investing exclusively in companies developing or enabling novel therapeutics for dementia, including Alzheimer's Disease.
DOMiNO Ventures is a venture capital firm backing high-tech, pure-digital, globally ambitious founders with roots in Eastern Europe, Central Asia, and the Caucasus, including diaspora talent. It also runs the BetterFuture AI Acceleration Program and pursues impact-oriented Better Future Goals.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.